First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

SMMART Program: A multi-omics tumour board with a focus on breast cancer

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Clinical validation of a targeted methylation-based multi-cancer early detection test

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC